Literature DB >> 2299210

Characteristics of Trichomonas vaginalis isolates from women with and without colpitis macularis.

J N Krieger1, P Wolner-Hanssen, C Stevens, K K Holmes.   

Abstract

Colpitis macularis, the most specific clinical sign for diagnosis of trichomoniasis, was detected by colposcopy in 52 of 118 infected women. Patients with colpitis macularis had a mean (+/- SD) of 18 +/- 20 Trichomonas vaginalis organisms/field (x 400 magnification) compared with 7 +/- 17 in patients with colpitis macularis (P less than .003). To compare possible virulence markers in isolates from women with and without colpitis macularis, isolates were analyzed for hemolytic activity, abscess production in an animal model, and adherence to cells in tissue culture. The mean hemolytic activity (relative to complete hemolysis) was 84% for 22 isolates from women with and 78% for 29 isolates from women without colpitis macularis. After subcutaneous injections in mice, abscesses were produced by 70% of isolates from patients with and 68% from patients without colpitis macularis. After a 15-min exposure, 39% of radiolabeled isolates from women with or without colpitis macularis adhered to HeLa cell monolayers. Purulent discharge, the second most useful sign for clinical diagnosis, was associated with colpitis macularis and with the number of organisms per high-power field on wet mount (P less than .01 for each comparison) but was not correlated with any experimental assay. Thus, no experimental characteristic of T. vaginalis isolates was associated with colpitis macularis or purulent vaginal discharge.

Entities:  

Mesh:

Year:  1990        PMID: 2299210     DOI: 10.1093/infdis/161.2.307

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Clinical and microbiological aspects of Trichomonas vaginalis.

Authors:  D Petrin; K Delgaty; R Bhatt; G Garber
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

2.  Molecular and phylogenetic analysis of PCR-amplified cyclin-dependent kinase (CDK) family sequences from representatives of the earliest available lineages of eukaryotes.

Authors:  D E Riley; J N Krieger
Journal:  J Mol Evol       Date:  1995-10       Impact factor: 2.395

3.  The vagina has reducing environment sufficient for activation of Trichomonas vaginalis cysteine proteinases.

Authors:  J F Alderete; D Provenzano
Journal:  Genitourin Med       Date:  1997-08

4.  Analysis of human immunoglobulin-degrading cysteine proteinases of Trichomonas vaginalis.

Authors:  D Provenzano; J F Alderete
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

5.  Trichomonas vaginalis contact-dependent cytolysis of epithelial cells.

Authors:  Gila Lustig; Christopher M Ryan; W Evan Secor; Patricia J Johnson
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

6.  Development of a polymerase chain reaction-based diagnosis of Trichomonas vaginalis.

Authors:  D E Riley; M C Roberts; T Takayama; J N Krieger
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

7.  Detection of variable DNA repeats in diverse eukaryotic microorganisms by a single set of polymerase chain reaction primers.

Authors:  D E Riley; M Samadpour; J N Krieger
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

8.  A novel neutrophil-activating factor released by Trichomonas vaginalis.

Authors:  M F Shaio; P R Lin; C S Lee; S C Hou; P Tang; K D Yang
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

9.  Antibody in sera of patients infected with Trichomonas vaginalis is to trichomonad proteinases.

Authors:  J F Alderete; E Newton; C Dennis; K A Neale
Journal:  Genitourin Med       Date:  1991-08

10.  Use of in vitro cytoadherence assays in the comparative study of the virulence of isolates of Trichomonas vaginalis.

Authors:  Lázara Rojas; Idalia Sariego; Jorge Fraga; Carlos A Sarría; Jorge Sarracent; Lizet Sánchez
Journal:  Parasitol Res       Date:  2004-06-08       Impact factor: 2.289

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.